Drug resistance in the HIV-1-infected paediatric population worldwide: A systematic review

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2032-2042

  Sánchez, Patricia Rojas ^a   Holguín, Africa ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiretroviral therapy; Children; HIV 1; Resistance mutations

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN;

AFRICA; AGE DISTRIBUTION; ANTIVIRAL RESISTANCE; ARTICLE; ASIA; ASSAY; BRAZIL; EUROPE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; PEDIATRICS; PUBLICATION; SPAIN; SYSTEMATIC REVIEW; THAILAND; UGANDA; UNITED KINGDOM; WESTERN HEMISPHERE; CHILD; DRUG EFFECTS; DRUG MONITORING; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84904557868     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku104     Document Type: Article

References (118)

1. Global report. UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2013/gr2013/UNAIDS_Global_Report2013_en.pdf (27 March 2013, date last accessed).
2. WHO, UNICEF, UNAIDS. 2011 Global HIV/AIDS Response Epidemic Update and Health Sector Progress towards Universal Access. http://www.who.int/ hiv/pub/progress_report2011/en/ (2 May 2013, date last accessed).
3. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458-65.
4. PENTA Steering Committee, Welch S, Sharland M et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591-613.
5. Judd A, Doerholt K, Tookey PA et al. Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC). Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45: 918-24.
6. Delaugerre C, Chaix ML, Blanche S et al. ANRS French Perinatal Cohort. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology 2009; 6: 85.
7. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/45/ whats-new-in-the-guidelines (4 February 2014, date last accessed).
8. Panel on Antiretroviral Therapy and Medical Management of HIVinfected Children. Guidelines for the Use of Antiretroviral Agents in Paediatric HIV Infection. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ pediatricguidelines.pdf (7 July 2013, date last accessed).
9. WHO The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. http://www. who.int/hiv/pub/guidelines/arv2013/download/en/ (18 September 2013, date last accessed).
10. Organización Panamericana de la Salud. Tratamiento antirretroviral de la infección por el VIH en niños en Latinoamérica y el Caribe: en la ruta hacia el acceso universal. Recomendaciones para un enfoque de salud pública. http://www2.paho.org/hq/dmdocuments/2008/GuiaARVninos. pdf (5 May 2013, date last accessed).
11. Briz V, León-Leal JA, Palladino C et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 2012; 31: 273-7.
12. Castro H, Judd A, Gibb DM et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study PLATO II. Lancet 2011; 377: 1580-7.
13. US Food and Drug Administration. Antiretroviral Drugs Used in the Treatment of HIV Infection. http://www.fda.gov/ForConsumers/ byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm (3 February 2013, date last accessed).
14. Persaud D, Palumbo P, Ziemniak C et al. Pediatric AIDS Clinical Trials Group P1030 Team. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195: 1402-10.
15. Zoufaly A, Fillekes Q, Hammerl R et al. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study. Antivir Ther 2013; 18: 681-90.
16. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
17. Kamya MR, Mayanja-Kizza H, Kambugu A et al. Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46: 187-93.
18. Zhao Y, Mu W, Harwell J, Zhou H et al. Drug resistance profiles among HIV-1 infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr 2011; 58: 47-53.
19. Musiime V, Kaudha E, Kayiwa J et al. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses 2013; 29: 449-55.
20. Bennett DE, Myatt M, Bertagnolio S et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther 2008; 12: 25-36.
21. WHO. HIV Resistance Report 2012. http://www.who.int/hiv/pub/ drugresistance/report2012/en/index.html (21 March 2013, date last accessed).
22. Sigaloff K, Calis J, Gleen S et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011; 11: 769-79.
23. Wamalwa D, Lehman D, Benki-Nugent S et al. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 62: 267-74.
24. Charpentier C, Gody JC, Mbitikon O et al. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses 2012; 28: 87-94.
25. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. J Int AIDS Soc 2013; 16: 18579.
26. Foster C, Judd A, Tookey P et al. Collaborative HIV Paediatric Study (CHIPS). Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDs 2009; 23: 159-66.
27. Dollfus C, Le Chenadec J, Faye A et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010; 51: 214-24.
28. de Mulder M, Yebra G, Navas A et al. Madrid Cohort of HIV-infected Children. High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain. PLoS One 2012; 7: e52155.
29. Nglazi MD, Kranzer K, Holele P et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis 2012; 12: 21.
30. WHO. Global HIV Drug Resistance Network. http://www.who.int/hiv/ topics/drugresistance/hivresnet/en/ (5 September 2013, date last accessed).
31. Roberts T, Bygrave H, Fajardo E et al. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 2012; 15: 17324.
32. WHO. Generic Protocol for Surveillance of Initial Drug-resistant HIV-1 Among Children ,18 Months of Age Newly Diagnosed with HIV. http:// apps.who.int/iris/bitstream/10665/75202/1/WHO_HIV_2012.17_eng.pdf (27 March 2013, date last accessed).
33. Thiam M, Diop-Ndiaye H, Kebe K et al. Performance of the ViroSeq HIV-1 genotyping system v2.0 on HIV-1 strains circulating in Senegal. J Virol Methods 2013; 188: 97-103.
34. Martínez-Cajas JL, Pant-Pai N, Klein MB et al. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008; 10: 212-23.
35. Koning FA, Castro H, Dunn D et al. Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2013; 68: 1220-36.
36. Megens S, Laethem KV. HIV-1 genetic variation and drug resistance development. Expert Rev Anti Infect Ther 2013; 11: 1159-78.
37. Alteri C, Artese A, Beheydt G et al. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. J Antimicrob Chemother 2013; 68: 2205-9.
38. Gupta R, Hill A, Sawyer AWet al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712-22.
39. Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-8.
40. Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
41. Yebra G, de Mulder M, Perez-Elias MJ et al. Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One 2011; 6: e26757.
42. Neogi U, Sahoo PN, De Costa A et al. High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naive perinatallyinfected children and adolescents with HIV-1 subtype C infection. BMC Infect Dis 2012; 12: 317.
43. Fokam J, Salpini R, SantoroMM et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J 2011; 30: 1062-8.
44. Towler WI, Barlow-Mosha L, Church JD et al. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses 2010; 26: 563-8.
45. de Mulder M, Yebra G, Navas A et al. Trends in drug resistance prevalence in HIV-1 infected children in Madrid: 1993 to 2010 analysis. Pediatr Infect Dis J 2012; 31: e213-21.
46. Parker MM, Wade N, Lloyd RM Jr et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003; 32: 292-7.
47. Almeida FJ, Rodrigues R, Zaparoli MS et al. Prevalence of transmitted HIV-1 drug resistance mutations in children and adolescents in São Paulo, Brazil. Pediatr Infect Dis J 2012; 31: e255-7.
48. Simonetti SR, Schatzmayr HG, Simonetti JP. Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz 2003; 98: 831-7.
49. Soto-Ramirez LE, Rodriguez-Diaz R, Harris DR et al. HIV drug resistance-associated mutations in antiretroviral naive HIV-1 infected Latin American children. Adv Virol 2010; 2010: 407476.
50. Holguín A, Erazo K, Escobar G et al. Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in Honduras and El Salvador during 1989-2009. Pediatr Infect Dis J 2011; 30: e82-7.
51. Parham L, de Rivera IL, Murillo W et al. Short communication: High prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. AIDS Res Hum Retroviruses 2011; 27: 1055-9.
52. Pérez L, Correa C, Campos YA et al. Drug-resistant HIV-1 in Cuban children and their seropositive mothers. MEDICC Rev 2011; 13: 24-31.
53. Castillo J, Arteaga G, Mendoza Y et al. HIV transmitted drug resistance in adult and pediatric populations in Panama. Rev Panam Salud Pública 2011; 30: 649-56.
54. Chakraborty R, Smith CJ, Dunn D et al. HIV-1 drug resistance in HIV-1 infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J 2008; 27: 457-9.
55. Frange P, Briand N, Avettand-Fenoel V et al. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. Pediatr Infect Dis J 2011; 30: 684-8.
56. Karchava M, Pulver W, Smith L et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006; 42: 614-9.
57. Lwembe R, Ochieng W, Panikulam A et al. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1 infected Kenya children with treatment failure. J Med Virol 2007; 79: 865-72.
58. Taylor BS, Hunt G, Abrams EJ et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27: 945-56.
59. Germanaud D, Derache A, Traore M et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1 infected children in Mali. J Antimicrob Chemother 2010; 65: 118-24.
60. Chaix ML, Rouet F, Kouakoussui KA et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cô te d'Ivoire. Pediatr Infect Dis J 2005; 24: 1072-6.
61. Vaz P, Chaix ML, Jani I et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009; 28: e283-7.
62. Fogel J, Li Q, Taha TE et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52: 1069-76.
63. Fogel JM, Mwatha A, Richardson P et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J 2013; 32: 164-9.
64. Kebe K, Thiam M, Diagne Gueye NR et al. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res Hum Retroviruses 2013; 29: 242-9.
65. Church JD, Mwatha A, Bagenda D et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in Ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 2009; 25: 673-7.
66. Ruel TD, Kamya MR, Li P et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011; 56: 44-50.
67. Al Hajjar SH, Frayha H, Althawadi S. Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy. Ann Saudi Med 2012; 32: 565-9.
68. Rath BA, von Kleist M, Castillo ME et al. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis. BMC Infect Dis 2013; 13: 1.
69. Dumans AT, Barreto CC, Santos AF et al. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtype B and F1 from children and adults patients under virological failure. Infect Genet Evol 2009; 9: 62-70.
70. Angelis DS, Tateno AF, Diaz RS et al. HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy. Braz J Infect Dis 2011; 15: 60-5.
71. Puthanakit T, Jourdain G, Hongsiriwon S et al. HIV-NAT 086 Study Team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010; 11: 565-72.
72. Lolekha R, Sirivichayakul S, Siangphoe U et al. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis 2005; 40: 309-12.
73. Westley BP, DeLong AK, Tray CS et al. Prediction of treatment failure using 2010 World Health Organization guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis 2012; 55: 432-40.
74. Mohamad S, Deris ZZ, Yusoff NK et al. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia. Braz J Infect Dis 2012; 16: 284-8.
75. Shet A, Neogi U, Sahoo PN et al. Effectiveness of first-line antiretroviral therapy and acquired drug resistance among HIV-1 infected children in India. Pediatr Infect Dis J 2013; 32: e227-9.
76. de Mulder M, York V,Wiznia AA et al. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center Pediatric Cohort, Bronx, NY, USA. HIV Med 2014; 15: 135-43.
77. Vaz P, Augusto O, Bila D et al. Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique. Clin Infect Dis 2012; 54: 369-74.
78. Yebra G, de Mulder M, Martín L et al. Cohort of Spanish AIDS Research Network (CoRIS). Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naive HIV-infected patients (CoRIS). Antiviral Res 2011; 89: 19-25.
79. Hemelaar J, Gouws E, Ghys PD et al. WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25: 679-89.
80. Holguín A, de Mulder M, Yebra G et al. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res 2008; 6: 327-34.
81. González-Alba JM, Holguín A, Garcia R et al. Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis. J Virol 2011; 85: 10755-63.
82. Yebra G, de Mulder M, Martín L et al. Cohort of the Spanish AIDS Research Network (CoRIS). Most HIV type 1 non-B infections in Spanish cohort of antiretroviral treatment-naive HIV-infected patients (CoRIS) are due to recombinant virases. J Clin Microbiol 2012; 50: 407-13.
83. Holguín A, Yebra G, Martín L et al. Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America. Clin Microbiol Infect 2013; 19: e523-32.
84. Murillo W, Veras N, Prosperi M et al. Single early introduction of HIV-1 subtype B into Central America accounts for most current cases. J Virol 2013; 87: 7463-70.
85. Pagán I, Holguín A. Reconstructing the timing and dispersion routes of HIV-1 subtype B epidemics in the Caribbean and Central America: a phylogenetic story. PLoS One 2013; 8: e69218.
86. Sanabani SS, Pessôa R, Soares de Oliveira AC et al. Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil. PLoS One 2013; 8: e62552.
87. Feng Y, Wei H, Hsi J et al. Identification of a novel HIV type 1 circulating recombinant form (CRF65_cpx) composed of CRF01_AE and subtypes B and C in western Yunnan, China. AIDS Res Hum Retroviruses 2014; doi:10.1089/aid.2013.0233.
88. Masquelier B, Bhaskaran K, Pillay D et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40: 505-11.
89. Ciccozzi M, Santoro MM, Giovanetti M et al. HIV-1 non-B subtypes in Italy: a growing trend. New Microbiol 2012; 35: 377-86.
90. von Wyl V, Kouyos RD, Yerly S et al. Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011; 204: 1095-103.
91. Santoro MM, Perno CF. HIV-1 genetic variability and clinical implications. ISRN Microbiol 2013; 2013: 481314.
92. Holguín Á , Ramírez de Arellano E, Rivas P et al. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 2006; 8: 98-107.
93. Vasan A, Renjifo B, Hertzmark E et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42: 843-52.
94. Easterbrook PJ, Smith M, Mullen J et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13: 4.
95. Bousheri S, Burke C, Ssewanyana I et al. Infection with different HIV subtypes is associated with CD4 activation-associated dysfunction and apoptosis. J Acquir Immune Defic Syndr 2009; 52: 548-52.
96. Touloumi G, Pantazis N, Pillay D et al. CASCADE Collaboration in EuroCoord. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clin Infect Dis 2013; 56: 888-97.
97. Bertagnolio S, Parkin NT, Jordan M et al. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 2010; 12: 195-208.
98. de Mulder M, Holguín A. Dried blood spots for monitoring HIV infection in public health programs in developing countries. Enferm Infecc Microbiol Clin 2013; 31: 100-7.
99. Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750-9.
100. Bannister WP, Cozzi-Lepri A, Clotet B et al. EuroSIDA Study Group. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA study. J Acquir Immune Defic Syndr 2008; 48: 324-33.
101. Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
102. Chaix ML, Descamps D, Wirden M et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23: 717-24.
103. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21: 1035-9.
104. Leigh Brown AJ, Frost SDW, Mathews WCet al. Transmission fitness of drug resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral treated population. J Infect Dis 2003; 187: 683-6.
105. Bezemer D, de Ronde A, Prins M et al. CASCADE Collaboration. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 2006; 11: 173-8.
106. Brenner B, Routy JP, Quan Y et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18: 1653-60.
107. Hauser A, Mugenyi K, Kabasinguzi R et al. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One 2011; 6: e20357.
108. Flys TS, Donnell D, Mwatha A et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195: 711-5.
109. WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. http://www.who.int/hiv/pub/mtct/ antiretroviral2010/en/ (7 June 2013, date last accessed).
110. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013; 18: 115-23.
111. Rawizza HE, Chaplin B, Meloni ST et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53: 1283-90.
112. Moore D, Awor A, Downing R et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49: 477-84.
113. Davies MA, Moultrie H, Eley B et al. Virologic failure and second-line antiretroviral therapy in children in South Africa: the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011; 56: 270-8.
114. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
115. Lidström J, Li Q, Hoover DR et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24: 381-6.
116. McIntyre JA, Hopley M, Moodley D et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6: e1000172.
117. Vignoles M, Barboni G, Agosti MR. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antivir Ther 2009; 14: 1175-81.
118. Fitzgerald F, Penazzato M, Gibb D. Development of antiretroviral resistance in children with HIV in low- and middle-income countries. J Infect Dis 2013; 207: 85-92.